Receptor protein tyrosine phosphatase delta (PTPRD) is a novel tumor suppressor that is widely inactivated in glioblastoma multiforme and several other malignancies. The mechanism(s) of action and the oncogenic context in which PTPRD acts remains largely unknown. This proposal focuses on defining the molecular foundations mediating the tumor suppressive function of PTPRD. Genetic analysis demonstrates that PTPRD and CDKN2A, which encodes the p16Ink4A cell cycle regulator, are frequently inactivated. Their concordant patterns of loss within human glioblastomas suggest that PTPRD may cooperate with CDKN2A during tumorigenesis. We will dissect the functional relationship of PTPRD and CDKN2A during tumorigenesis using the RCAS PDGF glioma mouse model and in vitro human astrocyte models. Studies will focus on determining the cooperative effects of PTPRD inactivation alone or in combination with CDKN2A deletion on tumor initiation and progression, cellular transformation, and alterations in signaling pathways important for cancer cell growth. Our preliminary data shows that STAT3 is a substrate of the PTPRD phosphatase, and recent work in our lab suggests that other substrates may exist. In order to define the molecular mechanisms mediating the tumor suppressive function of PTPRD, we propose to comprehensively characterize the substrate profile of PTPRD using a substrate TRAP assay in conjunction with mass spectrometry. The biological significance of the validated substrates will be investigated. With the completion of this proposal we will gain a better understanding of the molecular foundations of the PTPRD tumor suppressor in GBM, and provide insight into possible therapeutic targets and molecular tools for diagnosis.

Public Health Relevance

Our challenge for finding effective treatments for Glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, is to understand the molecular alterations that are driving tumorigenesis and their mechanism(s) of action. The goal of this project is to characterize the molecular mechanisms mediating the tumor suppressive function of PTPRD, one of the most frequently inactivated genes in GBM. This work will provide insight into possible targets for diagnostic and therapeutic intervention of this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Predoctoral Individual National Research Service Award (F31)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F09-A (08))
Program Officer
Bini, Alessandra M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Ortiz, Berenice; Fabius, Armida W M; Wu, Wei H et al. (2014) Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci U S A 111:8149-54
Ortiz, Berenice; White, Julie R; Wu, Wei H et al. (2014) Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Oncotarget 5:6976-82